Ibrutinib and ABT199 for CLL

Jennifer Brown, MD, PhD

Video Categories: ASH 2014

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

Related Videos

September 13, 2018

Genetic vs Genomic Testing: What’s the Difference?

Dr Andrey Antov provides a useful metaphor to explain how genetic testing and genomic testing differ from one another and the purpose behind each type of testing.

August 15, 2016

Addressing Optimal Surgical Conditions

Phillip Boudreaux, MD, discusses the difference in patient profiles in sick patients who undergo emergency surgeries versus healthier patients who undergo elective surgeries.